2nd-Gen TRK Inhibitors
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors

Released: November 09, 2021

Expiration: November 08, 2022

George D. Demetri
George D. Demetri, MD
Alexander E Drilon
Alexander E Drilon, MD

Activity

Progress
1
Course Completed

In this podcast episode, George D. Demetri, MD, and Alexander Drilon, MD, discuss emerging data on the efficacy, safety, and clinical role of second-generation TRK inhibitors that can overcome acquired resistance to first-generation agents in NTRK fusion–positive solid tumors. Topics include:

  • Mechanisms of acquired resistance to TRK inhibitor therapy
  • Clinical trial data on the second-generation inhibitors selitrectinib and repotrectinib
  • Safety profiles of first- vs second-generation TRK inhibitors